Abstracts - faqs.org

Abstracts

News, opinion and commentary

Search abstracts:
Abstracts » News, opinion and commentary

Visible Genetics reports gains from HIV treatment

Article Abstract:

Visible Genetics Inc. of Toronto, Ontario, sees improvement in HIV patients treated based on the specific genetic structure of the virus. According to the company's report, 39.1% of the patients tested with genotyping showed undetectable levels of HIV after six months, while only 9.5% of the control group treated with the standard drug showed undetectable viral levels. The report also indicated that viral load decreased six times in favor of therapy used with genotypic analysis. According to the company's CEO, John Stevens, the study is important because it shows taking into consideration the virus' genotype may be important in finding the right drug to be used on HIV patients.

Comment:

Sees improvement in HIV patients treated based on the specific genetic structure of the virus

Author: Zehr, Leonard
Publisher: Bell Globemedia Interactive
Publication Name: Globe & Mail (Toronto, Canada)
Subject: News, opinion and commentary
ISSN: 0319-0714
Year: 1998
Canada, Laboratory Apparatus and Furniture Manufacturing, Clinical Lab Equipment, Biomedical laboratory equipment, Visible Genetics Inc.

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Algene implements sweeping reorganization

Article Abstract:

Algene Biotechnologies Corp., based in Montreal, Quebec, is undertaking a reorganization program that will see cost-reduction, layoffs, new financing and a new CEO in the company, which intends to focus on research and development. Chairman and CEO Denis Gauvreau will retain the chairman title and the firm will look for a new CEO to head in implementing the company's commercial vision. The reorganization will include enhanced marketing strategies to maximize the company's commercial value and added effort to effect a research alliance on Alzheimer's disease.

Comment:

Is undertaking a reorganization program that will see cost-reduction, layoffs, new financing & a new CEO in the company

Author: Zehr, Leonard
Publisher: Bell Globemedia Interactive
Publication Name: Globe & Mail (Toronto, Canada)
Subject: News, opinion and commentary
ISSN: 0319-0714
Year: 1998
Strategy & planning, Medicine, Algene Biotechnologies Corp.

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Nexia Biotech produces genetically altered goat

Article Abstract:

Nexia Biotechnologies Inc. of Montreal, Quebec, has developed Canada's first genetically altered goat named Willow, producing revolutionary milk in its production farm in Ste-Anne-de-Bellevue. The Breed Early Lactate Early goat's milk is renowned for the lifesaving human protein incorporated into it. Nexia Biotechnologies president and chief executive officer Jeffrey Turner indicated that the value lies in the medical community's ability to create new proteins through transgenic animals in a cost effective and timely manner.

Comment:

Has developed the first genetically altered goat dubbed Willow producing revolutionary milk in its production farm

Author: Zehr, Leonard
Publisher: Bell Globemedia Interactive
Publication Name: Globe & Mail (Toronto, Canada)
Subject: News, opinion and commentary
ISSN: 0319-0714
Year: 1998
Genetic Engineering, Nexia Biotechnologies Inc.

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Article, Quebec
Similar abstracts:
  • Abstracts: Pulp mill sale lifts Crestbrook to profitability. Tembec selling non-core operations to reduce debt
  • Abstracts: Cendant reviews ex-chairman's travel expenses. Cendant hopes canceling merger allows growth
  • Abstracts: Barrington gives up fight against Sunoma. ASC starts hearings into stock fiasco at Cartaway. Hearing set on Manalta poison pill
  • Abstracts: Beetle's whimsical ads capture viewers' hearts. Recreating advertising
  • Abstracts: Canaccord snags C.M. Oliver. Canfor sees big savings from deal
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2023 Advameg, Inc.